Radiopharm Theranostics Ltd ADR Dossier
Qualitative Analysis
Business overview
Radiopharm Theranostics Ltd (ASX: RAD, NASDAQ: RADX) is an Australian-based, clinical-stage biopharmaceutical company specializing in the research, development, and commercialization of first-in-class radiopharmaceutical products. The company targets highly differentiated oncology biomarkers, intentionally avoiding crowded "me-too" targets like PSMA, FAP, or SSTR2. Its proprietary platforms span nanobodies, antibodies, small molecules, and peptides designed to address significant unmet needs in oncology. A key pillar of its development strategy is Radiopharm Ventures, LLC, a joint venture with The University of Texas MD Anderson Cancer Center, in which Radiopharm increased its ownership to 87.5% in January 2026.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the diagnostic performance evaluation of the small-molecule imaging agent RAD 101, which targets fatty acid synthase (FASN), in patients with recurrent brain metastases.
Expected impact: Establishment of a highly accurate PET imaging alternative to MRI for brain metastases, addressing a massive addressable market of over 300,000 annual diagnoses.
Evaluating the safety, dosimetry, and tumor uptake of the HER2-targeted single-domain antibody radiotherapeutic 177Lu-RAD202 in patients with advanced solid tumors.
Expected impact: First-in-class HER2-targeted radiopharmaceutical therapy validation, paving the way for Phase 2 therapeutic trials.
Accelerating the development of novel radiopharmaceutical candidates developed under the joint venture with MD Anderson Cancer Center, led by the B7-H3-targeting clinical asset 177Lu-BetaBart (RV-01).
Expected impact: Securing global leadership in systemic radiopharmaceuticals targeting the B7-H3 immune checkpoint protein.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To acquire a next-generation therapeutic radiopharmaceutical platform for prostate cancer designed to overcome resistance to existing prostate-specific membrane antigen (PSMA) targeting therapies.
Financial impact: Structured to minimize cash flow impact: paid 50% in cash and 50% in shares over two equal installments (at closing and on the first anniversary). Includes a contingent milestone payment of US$2.3 million in shares upon FDA IND clearance of a derived therapeutic product.
Strategic Partnerships
To apply Starpharma's proprietary DEP (dendrimer-enhanced product) platform technology to develop and manufacture a novel dendrimer-drug conjugate incorporating a Radiopharm radiopharmaceutical molecule.
Terms: Starpharma receives R&D service and manufacturing fees. Subject to successful development, Radiopharm can exercise an exclusive license option for a AUD $0.5 million option fee, followed by a AUD $2 million upfront payment, and up to AUD $89 million in success-based milestones plus royalties.
Co-developing innovative radiopharmaceuticals in Australia, including a basket clinical trial targeting multiple solid tumors. Lantheus also acts as a major strategic investor in Radiopharm.
Terms: Lantheus covers all clinical development costs for the program. Radiopharm is eligible to receive up to USD $2 million in milestone payments upon achieving key clinical objectives. Lantheus also made a A$12 million total strategic equity investment, holding a 14.5% stake as of late 2025.